MCID: PRT013
MIFTS: 58

Portal Hypertension

Categories: Rare diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 50 29 14
Hypertension, Portal 50 42 69
Hypertension Portal 52

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD10 33 K76.6
ICD9CM 35 572.3
MeSH 42 D006975
NCIt 47 C3119
SNOMED-CT 64 155821005 34742003
UMLS 69 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 50 portal hypertensionis abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. it may be caused by a variety of conditions, but cirrhosis is the most common cause in western countries. treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications. last updated: 2/1/2012

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to obstructive jaundice and antiphospholipid syndrome, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and TGF-Beta Pathway. The drugs Simvastatin and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system, which are the... more...

Related Diseases for Portal Hypertension

Diseases in the Portal Hypertension family:

Portal Hypertension Due to Infrahepatic Block

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
id Related Disease Score Top Affiliating Genes
1 obstructive jaundice 30.1 ALB EDN1 F2
2 antiphospholipid syndrome 29.7 EDN1 EDNRA
3 autoimmune hepatitis 29.1 EDN1 NOS3 TNF VEGFA
4 pericarditis 28.9 BMPR2 EDN1 NOS3 VEGFA
5 hereditary hemorrhagic telangiectasia 28.7 ALB F2 GPT TGFB1 TNF
6 lymphedema 26.3 ALB EDN1 F2 GPT SST TGFB1
7 portal hypertension, noncirrhotic 12.4
8 portal hypertension due to infrahepatic block 12.0
9 nodular regenerative hyperplasia 11.8
10 banti's syndrome 11.3
11 hypersplenism 11.2
12 splenomegaly 11.2
13 congenital hepatic fibrosis 11.1
14 caroli disease 11.1
15 portal vein thrombosis 11.0
16 polycystic kidney disease 4, with or without hepatic disease 10.8
17 budd-chiari syndrome 10.8
18 cholangitis, primary sclerosing 10.8
19 cerebroretinal microangiopathy with calcifications and cysts 10.8
20 non-hodgkin lymphoma, during pregnancy 10.8 ALB F2
21 progressive black carbon hyperpigmentation of infancy 10.7 EDN1 NOS3
22 congenital dyserythropoietic anemia 10.7 ALB TNF
23 adams-oliver syndrome 1 10.6
24 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 10.6
25 coach syndrome 10.6
26 littoral cell angioma of the spleen 10.6
27 myelofibrosis with myeloid metaplasia, somatic 10.6
28 cholestasis, progressive familial intrahepatic 3 10.6
29 adams-oliver syndrome 5 10.6
30 cerebroretinal microangiopathy with calcifications and cysts 2 10.6
31 cholestasis, progressive familial intrahepatic 2 10.6
32 adams-oliver syndrome 6 10.6
33 north american indian childhood cirrhosis 10.6
34 enamel erosion 10.6 CTC1 SST
35 angelucci's syndrome 10.6 ALB F2 SST
36 aryepiglottic fold cancer 10.5 ALB F2 SST
37 hepatitis 10.5
38 myopia 10.5 ALB EDN1 F2
39 fragile x syndrome type 2 10.5 ALB F2
40 broad ligament malignant neoplasm 10.5 AGTR1 ALB EDN1
41 burning mouth syndrome 10.5 F2 TNF
42 aortopulmonary window 10.5 AGTR1 EDN1 NOS3
43 lymphadenitis 10.4 AGTR1 EDN1 NOS3
44 hypertonia 10.4 NOS3 VEGFA
45 rete ovarii adenoma 10.4 ALB F2 TNF
46 argyria 10.4 F2 GPT
47 polymicrogyria, bilateral frontoparietal 10.4 AGTR1 EDN1 NOS3
48 dentinogenesis imperfecta 10.4 ALB F2 TNF
49 liver cirrhosis 10.4
50 lichen planus 10.4 NOS3 SST VEGFA

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Failure
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 JAK2 NOS3 SST TGFB1 THPO TNF
2 growth/size/body region MP:0005378 10.32 TNF VEGFA AGTR1 BMPR2 CTC1 EDN1
3 cardiovascular system MP:0005385 10.27 VEGFA AGTR1 BMPR2 EDN1 EDNRA F2
4 hematopoietic system MP:0005397 10.27 AGTR1 BMPR2 CTC1 EDNRA F2 JAK2
5 immune system MP:0005387 10.27 TNF VEGFA AGTR1 BMPR2 CTC1 EDNRA
6 cellular MP:0005384 10.26 ALB BMPR2 CTC1 EDNRA JAK2 NOS3
7 digestive/alimentary MP:0005381 10.25 ALB EDN1 EDNRA F2 NOS3 PKHD1
8 mortality/aging MP:0010768 10.25 JAK2 NOS3 PKHD1 SST TGFB1 TNF
9 endocrine/exocrine gland MP:0005379 10.22 ALB CTC1 EDN1 EDNRA JAK2 NOS3
10 embryo MP:0005380 10.14 BMPR2 EDN1 EDNRA F2 JAK2 TGFB1
11 nervous system MP:0003631 10.06 AGTR1 BMPR2 EDN1 EDNRA F2 NOS3
12 liver/biliary system MP:0005370 10.03 TNF UTS2 VEGFA ALB JAK2 NOS3
13 muscle MP:0005369 9.97 ALB BMPR2 EDN1 EDNRA NOS3 TGFB1
14 normal MP:0002873 9.96 ALB BMPR2 EDN1 EDNRA F2 JAK2
15 renal/urinary system MP:0005367 9.81 AGTR1 ALB BMPR2 EDN1 EDNRA NOS3
16 respiratory system MP:0005388 9.56 BMPR2 EDNRA F2 NOS3 PKHD1 TGFB1
17 skeleton MP:0005390 9.32 BMPR2 EDN1 EDNRA F2 JAK2 NOS3

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
2
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
3
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
4
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
5
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
6
Prazosin Approved Phase 4 19216-56-9 4893
7
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
8
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
10 Racepinephrine Approved Phase 4,Phase 2
11
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
14
Dalteparin Approved Phase 4,Phase 3 9005-49-6
15
Dipyridamole Approved Phase 4 58-32-2 3108
16
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
17 Nadroparin Approved Phase 4 9041-08-1
18
Warfarin Approved Phase 4,Phase 3 81-81-2 6691 54678486
19
Terlipressin Approved, Investigational Phase 4,Phase 3,Phase 2 14636-12-5 72081
20
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
21
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
22
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
23
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3 54-31-9 3440
24
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83150-76-9 383414 6400441
25
Lactulose Approved Phase 4,Phase 2 4618-18-2 11333
26
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
27
Tranexamic Acid Approved Phase 4 1197-18-8 5526
28
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
29 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
30
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
31 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
32 Antimetabolites Phase 4,Phase 3,Phase 2
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
34 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
35 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
36 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Adrenergic Agents Phase 4,Phase 3,Phase 2
38 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
39 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
41 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
42 Adrenergic alpha-Antagonists Phase 4,Phase 3
43 Antihypertensive Agents Phase 4,Phase 3,Phase 2
44 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
45 Autonomic Agents Phase 4,Phase 2,Phase 3
46 diuretics Phase 4,Phase 2,Phase 3
47 Isosorbide Phase 4
48 isosorbide-5-mononitrate Phase 4
49 Natriuretic Agents Phase 4,Phase 2,Phase 3
50 Nitric Oxide Donors Phase 4

Interventional clinical trials:

(show top 50) (show all 252)

id Name Status NCT ID Phase Drugs
1 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
2 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
3 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
4 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
6 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
7 Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
10 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
11 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
12 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
13 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
14 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
15 Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
16 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
17 Short Course Terlipressin for Control of Acute Variceal Bleeding Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
18 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
19 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
20 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
21 The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Completed NCT00534677 Phase 4 Terlipressin;Octreotide
22 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4 Albumin
23 The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients Completed NCT01049321 Phase 4
24 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
25 Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis Recruiting NCT02907749 Phase 4 Spironolactone;Carvedilol
26 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
27 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Recruiting NCT02994485 Phase 4 Simvastatin
28 Preventing Recurrent Bleeding After Eradication of Esophageal Varices Recruiting NCT02740166 Phase 4 propranolol
29 Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
30 Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Not yet recruiting NCT02945956 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu
31 Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir Not yet recruiting NCT02945982 Phase 4 Entecavir+Carvedilol+ Placebo;Entecavir+Carvedilol+ Fuzheng Huayu;Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis
32 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
33 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
34 Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
35 Sodium Restriction in the Management of Cirrhotic Ascites Terminated NCT00548366 Phase 4
36 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
37 Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
38 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
39 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
40 Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
41 ¹³C-Methacetin Breath Test (MBT) Methodology Study Unknown status NCT01205074 Phase 2, Phase 3 Non selective beta blocker - Propranolol
42 Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults Unknown status NCT00581087 Phase 3 DHEA treatment;Placebo
43 Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH) Completed NCT01000779 Phase 3 Propranolol
44 Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
45 Simvastatin Effect on Portal Hypertension Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
46 Danish Carvedilol Study in Portal Hypertension Completed NCT00493480 Phase 3 carvedilol;propranolol
47 Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
48 Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
49 Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope Completed NCT01131962 Phase 3
50 Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Completed NCT01654731 Phase 3 Bezafibrate;placebo

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

id Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

39
Liver, Spleen, Endothelial, Testes, Brain, Kidney, Bone

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 1027)
id Title Authors Year
1
Elastography methods for the non-invasive assessment of portal hypertension. ( 28856972 )
2017
2
Laparoscopic distal splenoadrenal shunt for the treatment of portal hypertension in children with congenital hepatic fibrosis: A case report. ( 28099341 )
2017
3
Non-invasive diagnosis of portal hypertension in cirrhosis using ultrasound based elastography. ( 28845498 )
2017
4
Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. ( 28940597 )
2017
5
Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension. ( 28626375 )
2017
6
Portal hypertension and its management in children. ( 28814423 )
2017
7
Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis. ( 28478151 )
2017
8
Pseudo Symmer's Pipe-Stem Fibrosis in Idiopathic Noncirrhotic Portal Hypertension Associated with POEMS Syndrome. ( 28848769 )
2017
9
Noninvasive assessment of portal hypertension and detection of esophageal varices in cirrhosis: state-of-the-art. ( 28079668 )
2017
10
Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. ( 28820885 )
2017
11
Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. ( 28824317 )
2017
12
An Unusual Case of Portal Hypertension Secondary to Primary Hypoplasia of the Portal Vein. ( 28892424 )
2017
13
Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension. ( 28079252 )
2017
14
Pathology of idiopathic non-cirrhotic portal hypertension. ( 28905307 )
2017
15
Portal hypertension as the initial manifestation of POEMS syndrome: a case report. ( 28503308 )
2017
16
Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. ( 28918131 )
2017
17
Wandering Spleen and Portal Hypertension: A Vicious Interplay. ( 28459078 )
2017
18
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension. ( 28855918 )
2017
19
Comparison of physical parameter measurements between peripheral and portal blood samples in patients with portal hypertension. ( 28946596 )
2017
20
Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. ( 27910154 )
2017
21
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. ( 27990835 )
2017
22
Spectrum of small-bowel mucosal abnormalities identified by capsule endoscopy in patients with portal hypertension of varied etiology. ( 28066855 )
2017
23
Combined caesarean with splenectomy in pregnancy with portal hypertension: defining plausibility. ( 28918404 )
2017
24
A Rare Cause of Portal Hypertension: Behcet's Disease and Nodular Regenerative Hyperplasia of the Liver. ( 28465872 )
2017
25
Management of Portal Hypertension After Liver Transplantation. ( 28838434 )
2017
26
Treatment of Refractory Gastrointestinal Bleeding in Patients With Portal Hypertension: A Case Series and Treatment Algorithm. ( 28923638 )
2017
27
Polycystic Liver Disease and Sarcoidosis: Unusual Coexisting Etiologies of Portal Hypertension. ( 28280650 )
2017
28
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. ( 26385087 )
2017
29
Current status of portal vein thrombosis in Japan: Results of a questionnaire survey by the Japan Society for Portal Hypertension. ( 28902450 )
2017
30
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. ( 27896916 )
2017
31
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis. ( 28822809 )
2017
32
Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy. ( 28295661 )
2017
33
Cholecystolithotomy Combined Armillarisin A versus Cholecystectomy in Cirrhotic Portal Hypertension Patients with Symptomatic Cholelithiasis. ( 28463673 )
2017
34
Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. ( 28836197 )
2017
35
Detailed EFSUM recommendations on the scope of ultrasound assessment in patients with portal hypertension considering the diagnostic reference level. ( 28856019 )
2017
36
Hepatic Disease with Portal Hypertension and Acute Juvenile Paracoccidioidomycosis: A Report of Two Cases and Literature Review. ( 28577123 )
2017
37
Amyloidosis: an unusual cause of portal hypertension. ( 27547738 )
2016
38
Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. ( 27500382 )
2016
39
Inflammatory Myofibroblastic Tumor of Liver Masquerading as Focal Nodular Hyperplasia in a Patient with Non-Cirrhotic Portal Hypertension and Biliary Pancreatitis. ( 27065695 )
2016
40
Idiopathic noncirrhotic portal hypertension: current perspectives. ( 27555800 )
2016
41
Pleuritic chest pain from portal hypertensive gastropathy in ESRD patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis. ( 27069969 )
2016
42
Enteroscopic Management of Ectopic Varices in a Patient with Liver Cirrhosis and Portal Hypertension. ( 27595025 )
2016
43
Portal hypertension: an uncommon clinical manifestation of Takayasu arteritis in a 9-year-old child. ( 27895519 )
2016
44
Laparoscopic azygoportal disconnection with and without splenectomy for portal hypertension. ( 27568650 )
2016
45
Invasive group B streptococcal infection in a patient with post splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension. ( 27006743 )
2016
46
Utility of per-oral cholangioscopy in the diagnosis of portal hypertension associated biliopathy. ( 27163346 )
2016
47
Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. ( 27589391 )
2016
48
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. ( 26734934 )
2016
49
Editorial: Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging. ( 27663418 )
2016
50
Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension. ( 27920483 )
2016

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 AGTR1 BMPR2 EDN1 EDNRA F2 JAK2
2
Show member pathways
13.39 AGTR1 F2 JAK2 TGFB1 THPO TNF
3
Show member pathways
13.27 BMPR2 JAK2 NOS3 TGFB1 THPO TNF
4
Show member pathways
13.19 BMPR2 EDN1 EDNRA F2 JAK2 NOS3
5
Show member pathways
13.16 ALB F2 JAK2 NOS3 TGFB1 THPO
6
Show member pathways
12.87 AGTR1 F2 JAK2 TGFB1 THPO UTS2
7
Show member pathways
12.49 AGTR1 EDN1 F2 JAK2 NOS3 TNF
8
Show member pathways
12.39 AGTR1 F2 JAK2 NOS3 TNF
9 11.86 ALB TGFB1 THPO VEGFA
10
Show member pathways
11.81 JAK2 TGFB1 TNF
11 11.77 EDN1 NOS3 VEGFA
12 11.71 TGFB1 TNF VEGFA
13 11.68 JAK2 TGFB1 TNF VEGFA
14 11.66 BMPR2 TGFB1 TNF
15 11.5 EDN1 TGFB1 TNF
16 11.5 BMPR2 EDN1 NOS3 TNF VEGFA
17 11.4 EDN1 NOS3 VEGFA
18 11.38 EDN1 EDNRA JAK2
19 11.16 AGTR1 EDN1 JAK2 NOS3 TGFB1 TNF
20 11.11 EDN1 EDNRA NOS3
21
Show member pathways
11.02 EDN1 JAK2 VEGFA
22 10.74 TGFB1 TNF

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 ALB EDN1 F2 SST TGFB1 THPO
2 extracellular space GO:0005615 9.36 ALB BMPR2 EDN1 F2 GPT SST
3 caveola GO:0005901 9.33 BMPR2 JAK2 NOS3
4 platelet alpha granule lumen GO:0031093 9.13 ALB TGFB1 VEGFA

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 EDN1 F2 JAK2 PKHD1 TGFB1 VEGFA
2 in utero embryonic development GO:0001701 9.9 EDN1 EDNRA NOS3 VEGFA
3 positive regulation of cell migration GO:0030335 9.89 EDN1 JAK2 TGFB1 VEGFA
4 positive regulation of protein kinase B signaling GO:0051897 9.81 TGFB1 THPO TNF
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 JAK2 TGFB1 VEGFA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 TGFB1 TNF VEGFA
7 regulation of cell proliferation GO:0042127 9.77 AGTR1 BMPR2 JAK2 TGFB1 TNF
8 positive regulation of fibroblast proliferation GO:0048146 9.75 CTC1 TGFB1 UTS2
9 positive regulation of endothelial cell migration GO:0010595 9.73 BMPR2 EDN1 VEGFA
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 EDN1 JAK2 TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.71 JAK2 TGFB1 TNF
12 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 NOS3 TGFB1 TNF
13 negative regulation of cell-cell adhesion GO:0022408 9.65 JAK2 TGFB1
14 response to hypoxia GO:0001666 9.65 EDN1 EDNRA TGFB1 UTS2 VEGFA
15 positive regulation of fibroblast migration GO:0010763 9.63 TGFB1 UTS2
16 branching involved in blood vessel morphogenesis GO:0001569 9.63 EDN1 EDNRA VEGFA
17 artery smooth muscle contraction GO:0014824 9.62 EDN1 EDNRA
18 regulation of blood pressure GO:0008217 9.62 EDN1 EDNRA NOS3 UTS2
19 negative regulation of platelet activation GO:0010544 9.61 F2 NOS3
20 endothelial cell apoptotic process GO:0072577 9.61 BMPR2 TNF
21 positive regulation of collagen biosynthetic process GO:0032967 9.61 F2 TGFB1 UTS2
22 positive regulation of axon extension involved in axon guidance GO:0048842 9.58 BMPR2 VEGFA
23 positive regulation of protein complex assembly GO:0031334 9.58 TGFB1 TNF VEGFA
24 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.57 EDN1 NOS3
25 positive regulation of odontogenesis GO:0042482 9.52 EDN1 TGFB1
26 positive regulation of mononuclear cell migration GO:0071677 9.51 TGFB1 TNF
27 positive regulation of MAP kinase activity GO:0043406 9.46 EDN1 TGFB1 TNF VEGFA
28 positive regulation of protein phosphorylation GO:0001934 9.35 F2 TGFB1 THPO TNF VEGFA
29 regulation of blood vessel diameter GO:0097746 9.34 AGTR1
30 positive regulation of cytosolic calcium ion concentration GO:0007204 9.02 AGTR1 EDN1 EDNRA JAK2 UTS2

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 F2 TGFB1 THPO VEGFA
2 hormone activity GO:0005179 9.26 EDN1 SST THPO UTS2
3 cytokine activity GO:0005125 9.02 EDN1 TGFB1 THPO TNF VEGFA

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....